Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment
Background Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an absence of CD4+ T-cell decrease has been observed in non-responders. Herein, we describe CD4+ T-cell changes over repeated cycles of rituximab and their relationship with clinical outcomes. Methods Patients with rheumatoid arthritis who started rituximab between July 2007 and July 2013 were analyzed up to November 2014. Lymphocyte phenotyping and clinical assessment... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Reihe/Periodikum: | Arthritis research & therapy |
Verlag/Hrsg.: |
London,
BioMed Central
|
Sprache: | Englisch |
ISSN: | 1478-6354 |
Weitere Identifikatoren: | doi: 10.1186/s13075-016-1152-5 |
Permalink: | https://search.fid-benelux.de/Record/olc-benelux-198630986X |
URL: | NULL NULL |
Datenquelle: | Online Contents Benelux; Originalkatalog |
Powered By: | Verbundzentrale des GBV (VZG) |
Link(s) : | http://dx.doi.org/10.1186/s13075-016-1152-5
http://dx.doi.org/10.1186/s13075-016-1152-5 |
Wird geladen...